Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children. 10 to 15% of pediatric cases are of T cell origin (T-ALL). Current intensive multidrug therapy can achieve high cure rates, yet associated with serious long-term adverse effects, including secondary cancers. Moreover, 15% of children will relapse, facing a poor prognosis. We previously […]
Read More